Axon Enterprise, Inc $AXON is Lee Johnson Capital Management LLC's 6th Largest Position

Key Points

• Lee Johnson Capital Management LLC increased its stake in Axon Enterprise, Inc by 19.1% in the 2nd quarter, now holding approximately 8,687 shares valued at $7.19 million.
• Institutional investors now own around 79.08% of Axon Enterprise stock, following significant purchases from firms like Jennison Associates and Vanguard Group.
• Wall Street analysts are optimistic about Axon Enterprise, with a majority rating it as a "Buy" and setting a price target range between $825.00 and $900.00.

Lee Johnson Capital Management LLC lifted its stake in Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 19.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 8,687 shares of the biotechnology company's stock after purchasing an additional 1,393 shares during the period. Axon Enterprise accounts for about 2.5% of Lee Johnson Capital Management LLC's investment portfolio, making the stock its 6th biggest holding. Lee Johnson Capital Management LLC's holdings in Axon Enterprise were worth $7,192,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of AXON. Jennison Associates LLC lifted its position in shares of Axon Enterprise by 23,203.7% in the 1st quarter. Jennison Associates LLC now owns 614,053 shares of the biotechnology company's stock worth $322,961,000 after purchasing an additional 611,418 shares during the period. Nuveen LLC purchased a new stake in shares of Axon Enterprise in the 1st quarter worth about $264,796,000. Westfield Capital Management Co. LP lifted its position in shares of Axon Enterprise by 29.8% in the 1st quarter. Westfield Capital Management Co. LP now owns 927,801 shares of the biotechnology company's stock worth $487,977,000 after purchasing an additional 212,931 shares during the period. Vanguard Group Inc. lifted its position in shares of Axon Enterprise by 2.2% in the 1st quarter. Vanguard Group Inc. now owns 8,632,008 shares of the biotechnology company's stock worth $4,540,005,000 after purchasing an additional 185,571 shares during the period. Finally, Axiom Investors LLC DE purchased a new stake in shares of Axon Enterprise in the 1st quarter worth about $93,088,000. 79.08% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Axon Enterprise news, CFO Brittany Bagley sold 870 shares of Axon Enterprise stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $773.25, for a total value of $672,727.50. Following the completion of the transaction, the chief financial officer directly owned 113,022 shares of the company's stock, valued at approximately $87,394,261.50. The trade was a 0.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Patrick W. Smith sold 10,000 shares of Axon Enterprise stock in a transaction that occurred on Monday, August 11th. The stock was sold at an average price of $831.29, for a total transaction of $8,312,900.00. Following the completion of the sale, the chief executive officer owned 3,053,982 shares of the company's stock, valued at $2,538,744,696.78. This represents a 0.33% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 44,932 shares of company stock valued at $34,408,816. 5.70% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on AXON. Wolfe Research initiated coverage on shares of Axon Enterprise in a research report on Monday, July 7th. They issued an "outperform" rating for the company. Piper Sandler initiated coverage on shares of Axon Enterprise in a research note on Tuesday, September 23rd. They issued an "overweight" rating and a $893.00 price target for the company. JPMorgan Chase & Co. increased their price target on shares of Axon Enterprise from $730.00 to $850.00 and gave the stock an "overweight" rating in a research note on Thursday, July 17th. JMP Securities reiterated a "market outperform" rating and issued a $825.00 price target on shares of Axon Enterprise in a research note on Monday. Finally, Craig Hallum upgraded shares of Axon Enterprise from a "hold" rating to a "buy" rating and set a $900.00 price target for the company in a research note on Tuesday, August 5th. Fourteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $841.64.

Axon Enterprise Stock Up 1.0%

Shares of Axon Enterprise stock opened at $716.02 on Tuesday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.71 and a current ratio of 2.95. The stock has a market capitalization of $56.21 billion, a PE ratio of 176.80, a price-to-earnings-growth ratio of 27.53 and a beta of 1.40. Axon Enterprise, Inc has a 52-week low of $394.24 and a 52-week high of $885.91. The company has a 50-day simple moving average of $757.89 and a two-hundred day simple moving average of $704.87.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last issued its earnings results on Monday, August 4th. The biotechnology company reported $2.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.54 by $0.58. The business had revenue of $668.54 million during the quarter, compared to analysts' expectations of $641.77 million. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The business's revenue for the quarter was up 32.6% compared to the same quarter last year. During the same period in the previous year, the company earned $1.20 earnings per share. Axon Enterprise has set its FY 2025 guidance at EPS. On average, analysts anticipate that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axon Enterprise, Inc (NASDAQ:AXON - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.